COSTA MESA, Calif.--(BUSINESS WIRE)--Synthetic Blood International, Inc. (OTCBB:SYBD) today announced that The United States Department of Defense (DoD) has approved the award of a $1.9 million grant to M. Ross Bullock, M.D., Ph.D., of the University of Miami Miller School of Medicine, Department of Neurosurgery and principal investigator for the Company’s planned Phase IIb clinical trial with Oxycyte™ for the treatment of traumatic brain injury (TBI). Oxycyte is the Company’s perfluorocarbon (PFC) therapeutic oxygen carrier and blood substitute.
